Volume 10, Number 3—March 2004
Dispatch
Endemic Carbapenem-resistant Pseudomonas aeruginosa with Acquired Metallo-β-lactamase Determinants in European Hospital
Table 2
Drug resistance profileb | blaVIM status |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
blaVIM-1 (n = 54) (%) | blaVIM-2 (n = 10) (%) | blaVIM-negative (n = 25) (%) | ||||||||||
Imi |
Mem |
Caz |
Pip |
Atm |
Ak |
Gm |
Tob |
Cip |
39 (72) |
10 (100) |
7 (28) |
|
Imi |
Mem |
Caz |
Pip |
Atm |
Gm |
Tob |
Cip |
11 (20) |
- |
6 (24) |
||
Imi |
Mem |
Caz |
Pip |
Gm |
Tob |
Cip |
1 (2) |
- |
1 (4) |
|||
Imi |
Mem |
Caz |
Pip |
Ak |
Gm |
Tob |
Cip |
2 (4) |
- |
- |
||
Imi |
Mem |
Caz |
Ak |
Gm |
Tob |
Cip |
1 (2) |
- |
- |
|||
Otherc | - | - | 11 (44) |
aAll isolates were susceptible to polymixin B. The percentage of isolates resistant to all the tested drugs (except polymixin B) was significantly higher among blaVIM-positive isolates (76 vs. 28%; p < 0.001, according to the χ2 test).
bImi, imipenem; Mem, meropenem; Caz, ceftazidime; Pip, piperacillin; Atm, aztreonam; Ak, amikacin; Gm, gentamicin; Tob, tobramycin; Cip, ciprofloxacin.
cStrains resistant to fewer than 5 antibiotics.
Page created: February 08, 2011
Page updated: February 08, 2011
Page reviewed: February 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.